Prostate Adenocarcinoma: Clinical Trials

105 trials for Prostate Adenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

34 completed, 23 recruiting, 21 active not recruiting, 17 terminated. 105 Phase 2, 9 Phase 1, 2 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 2105Completed 34, Recruiting 23, Active not recruiting 21, Terminated 17, Withdrawn 4, Not yet recruiting 3, Unknown 2, Suspended 1
Phase 19Completed 4, Terminated 3, Active not recruiting 1, Unknown 1
Phase 32Completed 2

Follow Prostate Adenocarcinoma: new trials by email Literature Review of Prostate Adenocarcinoma trials Research Report on Prostate Adenocarcinoma

Trials (filtered) newest first · largest first

All 105 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Whole Versus Partial Gland Boost During Prostate SBRT
Prostate stereotactic body radiotherapy with whole gland boost, Prostate stereotactic body radiotherapy with DIL boost - Prostate Cancer, Prostate Adenocarcinoma
Phase 2Not yet recruitingUniversity of Nebraska1602026-12-252026-11-03
Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial
Abiraterone Acetate, Biospecimen Collection, Leuprolide Acetate - Recurrent Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2RecruitingMayo Clinic2022026-08-042026-09-18
Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer
Radiation therapy - Prostate Adenocarcinoma
Phase 2RecruitingUniversity of California, San Diego1502026-07-202026-08-04
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
Exercise Therapy - Prostate Cancer, Prostate Adenocarcinoma
Phase 2RecruitingCity of Hope Medical Center1022026-07-132026-10-30
A Study of Lower Dose Radiation Therapy for People With Prostate Cancer
MR-guided Stereotactic Body Radiation Therapy - Prostate Cancer, Prostate Adenocarcinoma
Phase 2RecruitingMemorial Sloan Kettering Cancer Center542026-05-282026-06-18
Study of Recurrence-directed Therapy (RDT) With or Without Androgen-Deprivation Therapy (ADT) In Patients With Radio-recurrent Oligo-metastatic Hormone/Castrate Sensitive Prostate Cancer (romCSPC)
Recurrence-directed therapy (RDT), ELIGARD 22.5mg - Prostate Adenocarcinoma, Castration Sensitive Prostate Cancer
Phase 2RecruitingOntario Clinical Oncology Group (OCOG)1622026-05-062026-10-13
Utilization of Flotufolastat 18F PET for Post-Focal Therapy Prostate Cancer Evaluation
Flotufolastat F18 PET - Prostate Adenocarcinoma, Prostate Cancer
Phase 2Not yet recruitingUniversity of California, Irvine602026-05-012026-05-06
INSPIRE: INnovative SABR for Prostate Cancer All IREland
Next generation Stereotactic Ablative Radiotherapy (SABR) - Prostate Adenocarcinoma
Phase 2RecruitingCancer Trials Ireland1362026-04-232026-07-06
Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance
rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®), Flotufolastat F18 - Prostatic Neoplasms, Prostate Cancer
Phase 2RecruitingIcahn School of Medicine at Mount Sinai1202026-02-102026-02-23
Neoadjuvant Embolization and Cytoreduction in Prostate Cancer
Prostatic Artery Embolization - Prostate Adenocarcinoma
Phase 2Not yet recruitingSrinivas Raman352026-02-012025-11-26
Proof-of-Concept Trial to Assess the Efficacy and Safety of Fezolinetant in Improving Vasomotor Symptoms in Men With Prostate Cancer Undergoing Androgen Deprivation Therapy
fezolinetant - reference formulation, Placebo - Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Phase 2RecruitingShehzad Basaria, M.D.602026-01-142026-08-17
Androgen Deprivation Therapy (Relugolix) for the Improvement of Diagnostic Imaging (PSMA PET/CT Scan) in Patients With High Risk or Very High Risk Prostate Cancer, The EnrichPSMA Trial
Biospecimen Collection, Computed Tomography, Flotufolastat F-18 Gallium - Prostate Adenocarcinoma, Stage IIC Prostate Cancer AJCC v8
Phase 2RecruitingMayo Clinic302025-08-252026-09-23
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
Lu-17-PSMA-617 - Prostate Adenocarcinoma
Phase 2RecruitingHackensack Meridian Health542025-03-052026-03-23
EBRT and HDR Brachytherapy for Unfavorable-intermediate, High, and Very High-risk Prostate Cancer
External Beam Radiation, HDR Brachytherapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma
Phase 2Active not recruitingUniversity of Virginia602025-01-302026-04-27
A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
Relacorilant, Enzalutamide, Placebo (Sugar Pill) - Prostate Cancer, Prostate Adenocarcinoma
Phase 2RecruitingUniversity of Chicago902025-01-062026-08-31
Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
Biopsy Procedure, Biospecimen Collection, Placebo Administration - Prostate Adenocarcinoma
Phase 2RecruitingNational Cancer Institute (NCI)902024-09-122026-10-27
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Biopsy, Biospecimen Collection, Computed Tomography - Prostate Adenocarcinoma
Phase 2RecruitingSean Sachdev502024-09-062026-10-30
Effects of Relugolix vs Leuprolide on Cardiac Function in Patients With Prostate Cancer
Biospecimen Collection, Contrast Agent, Leuprolide - Prostate Adenocarcinoma, Stage IIB Prostate Cancer AJCC v8
Phase 2RecruitingOhio State University Comprehensive Cancer Center702024-08-122026-03-09
PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer
Para Aortic Radiation Therapy: Photon Therapy, Para Aortic Radiation Therapy: Proton Therapy, Androgen Deprivation Therapy - Prostate Cancer, Prostate Adenocarcinoma
Phase 2RecruitingUniversity of Miami342024-07-032026-06-16
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Phase 2TerminatedUniversity of Washington82024-05-232026-10-19

Showing 20 of 105. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (74)  ·  Adenocarcinoma Of Esophagus (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Adenocarcinoma (1)  ·  Adenocarcinoma of Lung (1)  ·  Anus Neoplasms (1)  ·  Carcinoma, Hepatocellular (1)  ·  Carcinoma, Ovarian Epithelial (1)  ·  Carcinoma, Renal Cell (1)  ·  Carcinoma, Transitional Cell (1)  ·  Cholangiocarcinoma (1)  ·  Colorectal Neoplasms (1)  ·  Erectile Dysfunction (1)  ·  Fasting (1)  ·  Genital Neoplasms, Male (1)

Broader conditions

Genital Diseases (76)  ·  Male Urogenital Diseases (76)  ·  Neoplasms (76)  ·  Neoplasms by Site (76)  ·  Urogenital Diseases (76)  ·  Genital Diseases, Male (75)  ·  Prostatic Diseases (74)  ·  Urogenital Neoplasms (74)  ·  Genital Neoplasms, Male (73)  ·  Pathological Conditions, Signs and Symptoms (6)  ·  Neoplastic Processes (3)  ·  Pathologic Processes (3)  ·  Signs and Symptoms (3)  ·  Breast Diseases (2)  ·  Breast Neoplasms (2)

Interventions

Magnetic Resonance Spectroscopy (19)  ·  Leuprolide (13)  ·  Specimen Handling (13)  ·  Goserelin (10)  ·  luprolide acetate gel depot (10)  ·  Abiraterone Acetate (9)  ·  Androgen Antagonists (9)  ·  Prednisone (8)  ·  apalutamide (7)  ·  Radiosurgery (6)  ·  X-Rays (6)  ·  enzalutamide (6)  ·  gallium 68 PSMA-11 (6)  ·  Docetaxel (5)  ·  Glutamate Carboxypeptidase II (5)

Sponsors

National Cancer Institute (NCI) (10)  ·  University of Washington (9)  ·  M.D. Anderson Cancer Center (8)  ·  Mayo Clinic (7)  ·  Jonsson Comprehensive Cancer Center (4)  ·  Andrei Iagaru (3)  ·  City of Hope Medical Center (3)  ·  Memorial Sloan Kettering Cancer Center (3)  ·  University of California, San Francisco (3)  ·  University of Utah (3)  ·  Emory University (2)  ·  NRG Oncology (2)  ·  Ohio State University Comprehensive Cancer Center (2)  ·  Roswell Park Cancer Institute (2)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2)

Countries

United States (91)  ·  Canada (7)  ·  France (3)  ·  Belgium (1)  ·  Brazil (1)  ·  Cyprus (1)  ·  Ireland (1)  ·  Netherlands (1)  ·  Portugal (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Michael Schweizer (4)  ·  Christopher Logothetis (3)  ·  Amar Kishan (2)  ·  Andrei Iagaru (2)  ·  Carlos E. Vargas, M.D. (2)  ·  Evan Yu (2)  ·  Paul Corn (2)  ·  Rahul Aggarwal, MD (2)  ·  Alejandro Sanchez (1)  ·  Amar Kishan, MD (1)  ·  Andrei Iagaru, MD (1)  ·  Andrew A Loblaw (1)  ·  Andrew McDonald, MD (1)  ·  Ashesh Jani, MD, MSEE (1)

Results publications

PMID 15683820, PMID 20818327, PMID 25847934, PMID 29876010, PMID 30700328, PMID 30811282, PMID 31478089, PMID 31515154, PMID 33602654, PMID 33674398, PMID 34326126, PMID 34406051, PMID 34663638, PMID 35277461, PMID 36200668, PMID 37178932, PMID 37419394, PMID 37555901, PMID 37619656, PMID 38423030, PMID 38664016, PMID 39074346, PMID 39390760, PMID 39848765, PMID 40906325, PMID 41202201, PMID 41223345, PMID 41378786, PMID 41467749, PMID 41698328, PMID 42377125, PMID 8892467

NIH funding

P30CA008748 (2), P30CA015083 (2), P30CA015704 (2), P30CA016672 (2), P30CA060553 (2), P30CA138292 (2), U01CA062491 (2), U10CA180868 (2), 2018 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00100 (1), N01CM62202 (1), N01CM62205 (1)